Asp Michelle L, Sjaastad Frances V, Siddiqui Jalal K, Davis Jonathan P, Metzger Joseph M
Department of Integrative Biology and Physiology, University of Minnesota Medical School, Minneapolis, Minnesota.
Department of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio.
Biophys J. 2016 May 10;110(9):2094-105. doi: 10.1016/j.bpj.2016.03.037.
Cardiac gene delivery of parvalbumin (Parv), an EF-hand Ca(2+) buffer, has been studied as a therapeutic strategy for diastolic heart failure, in which slow Ca(2+) reuptake is an important contributor. A limitation of wild-type (WT) Parv is the significant trade-off between faster relaxation and blunted contraction amplitude, occurring because WT-Parv sequesters Ca(2+) too early in the cardiac cycle and prematurely truncates sarcomere shortening in the facilitation of rapid relaxation. We recently demonstrated that an E → Q substitution (ParvE101Q) at amino acid 12 of the EF-hand Ca(2+)/Mg(2+) binding loop disrupts bidentate Ca(2+) binding, reducing Ca(2+) affinity by 99-fold and increasing Mg(2+) affinity twofold. ParvE101Q caused faster relaxation and not only preserved contractility, but unexpectedly increased it above untreated myocytes. To gain mechanistic insight into the increased contractility, we focused here on amino acid 12 of the EF-hand motif. We introduced an E → D substitution (ParvE101D) at this site, which converts bidentate Ca(2+) coordination to monodentate coordination. ParvE101D decreased Ca(2+) affinity by 114-fold and increased Mg(2+) affinity 28-fold compared to WT-Parv. ParvE101D increased contraction amplitude compared to both untreated myocytes and myocytes with ParvE101Q, with limited improvement in relaxation. Additionally, ParvE101D increased spontaneous contractions after pacing stress. ParvE101D also increased Ca(2+) transient peak height and was diffusely localized around the Z-line of the sarcomere, suggesting a Ca(2+)-dependent mechanism of enhanced contractility. Sarcoplasmic reticulum Ca(2+) load was not changed with ParvE101D, but postpacing Ca(2+) waves were increased. Together, these data show that inverted Ca(2+)/Mg(2+) binding affinities of ParvE101D increase myocyte contractility through a Ca(2+)-dependent mechanism without altering sarcoplasmic reticulum Ca(2+) load and by increasing unstimulated contractions and Ca(2+) waves. ParvE101D provides mechanistic insight into how changes in the Ca(2+)/Mg(2+) binding affinities of parvalbumin's EF-hand motif alter function of cardiac myocytes. These data are informative in developing new Ca(2+) buffering strategies for the failing heart.
肌浆蛋白(Parv)是一种EF手型钙缓冲蛋白,其心脏基因递送已被研究作为舒张性心力衰竭的一种治疗策略,其中缓慢的钙再摄取是一个重要因素。野生型(WT)肌浆蛋白的一个局限性是在更快的舒张和减弱的收缩幅度之间存在显著的权衡,这是因为WT - 肌浆蛋白在心动周期中过早地螯合钙,并在促进快速舒张的过程中过早地截断肌节缩短。我们最近证明,在EF手型钙/镁结合环的第12位氨基酸处进行E→Q替换(ParvE101Q)会破坏双齿钙结合,使钙亲和力降低99倍,并使镁亲和力增加两倍。ParvE101Q导致更快的舒张,不仅保留了收缩力,而且出乎意料地使其高于未处理的心肌细胞。为了深入了解收缩力增加的机制,我们在此关注EF手型基序的第12位氨基酸。我们在该位点引入了E→D替换(ParvE101D),这将双齿钙配位转变为单齿配位。与WT - 肌浆蛋白相比,ParvE101D使钙亲和力降低114倍,镁亲和力增加28倍。与未处理的心肌细胞和表达ParvE101Q的心肌细胞相比,ParvE101D增加了收缩幅度,舒张改善有限。此外,ParvE101D在起搏应激后增加了自发收缩。ParvE101D还增加了钙瞬变峰值高度,并在肌节的Z线周围呈弥漫性定位,提示收缩力增强的钙依赖机制。肌浆网钙负荷在ParvE101D处理后没有变化,但起搏后钙波增加。总之,这些数据表明ParvE101D的钙/镁结合亲和力倒置通过钙依赖机制增加心肌细胞收缩力,而不改变肌浆网钙负荷,并通过增加非刺激收缩和钙波来实现。ParvE101D为肌浆蛋白EF手型基序的钙/镁结合亲和力变化如何改变心肌细胞功能提供了机制性见解。这些数据对于开发针对衰竭心脏的新钙缓冲策略具有参考价值。